{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:40:32Z","timestamp":1774262432157,"version":"3.50.1"},"reference-count":28,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2019,10,10]]},"DOI":"10.1253\/circrep.cr-19-0070","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T18:18:50Z","timestamp":1569521930000},"page":"405-413","source":"Crossref","is-referenced-by-count":28,"title":["Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1253","volume":"1","author":[{"given":"Masaki","family":"Nakagaito","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Joho","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Ushijima","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: An update. <i>Diabetes Care<\/i> 2004; 27: 1879\u20131884.","DOI":"10.2337\/diacare.27.8.1879"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>Eur Heart J<\/i> 2008; 29: 1377\u20131385.","DOI":"10.1093\/eurheartj\/ehn153"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. <i>Circulation<\/i> 2001; 103: 2668\u20132673.","DOI":"10.1161\/01.CIR.103.22.2668"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Murcia AM, Hennekens CH, Lamas GA, Jim\u00e9nez-Navarro M, Rouleau JL, Flaker GC, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. <i>Arch Intern Med<\/i> 2004; 164: 2273\u20132279.","DOI":"10.1001\/archinte.164.20.2273"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gilbert RE, Krum H. Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. <i>Lancet<\/i> 2015; 385: 2107\u20132117.","DOI":"10.1016\/S0140-6736(14)61402-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. <i>N Engl J Med<\/i> 2008; 358: 2545\u20132559.","DOI":"10.1056\/NEJMoa0802743"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. <i>N Engl J Med<\/i> 2008; 359: 1577\u20131589.","DOI":"10.1056\/NEJMoa0806470"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>N Engl J Med<\/i> 2013; 369: 1317\u20131326.","DOI":"10.1056\/NEJMoa1307684"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: A meta-analysis of randomised controlled trials. <i>Lancet Diabetes Endocrinol<\/i> 2015; 3: 356\u2013366.","DOI":"10.1016\/S2213-8587(15)00044-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <i>N Engl J Med<\/i> 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med<\/i> 2017; 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med<\/i> 2019; 380: 347\u2013357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 2015; 17: 1180\u20131193.","DOI":"10.1111\/dom.12572"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. <i>Diab Vasc Dis Res<\/i> 2016; 13: 119\u2013126.","DOI":"10.1177\/1479164115616901"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet<\/i> 2019; 393: 31\u201339.","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, Nakamori S, et al. Diuretic effects of sodium\u2013glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. <i>Int J Cardiol<\/i> 2015; 201: 1\u20133.","DOI":"10.1016\/j.ijcard.2015.07.072"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Seo Y, Yamamoto M, Machino-Ohtsuka T, Ishizu T, Aonuma K. Effect and safety of sodium glucose cotransporter 2 inhibitors in diabetes patients with drug-refractory advanced heart failure. <i>Circ J<\/i> 2018; 82: 1959\u20131962.","DOI":"10.1253\/circj.CJ-18-0171"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. <i>Pharmacol Ther<\/i> 2013; 139: 51\u201359.","DOI":"10.1016\/j.pharmthera.2013.04.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. <i>Am J Physiol Endocrinol Metab<\/i> 2013; 304: E117\u2013E130.","DOI":"10.1152\/ajpendo.00439.2012"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. <i>J Pharmacol Sci<\/i> 2016; 130: 159\u2013169.","DOI":"10.1016\/j.jphs.2016.02.003"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Miyata M, Sasaki T, Ikeda Y, Shinsato T, Kubozono T, Furusho Y, et al. Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF). <i>J Cardiol<\/i> 2012; 59: 352\u2013358.","DOI":"10.1016\/j.jjcc.2011.12.007"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishio M, Ohtani T, et al. Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. <i>Cardiovasc Res<\/i> 2005; 68: 118\u2013127.","DOI":"10.1016\/j.cardiores.2005.05.023"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. <i>N Engl J Med<\/i> 1984; 311: 819\u2013823.","DOI":"10.1056\/NEJM198409273111303"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Joho S, Akabane T, Ushijima R, Hirai T, Kinugawa K. Sympathetic nerve activity efferent drive and beta-blocker treatment: Effect of interaction in systolic heart failure. <i>Circ J<\/i> 2016; 80: 2149\u20132154.","DOI":"10.1253\/circj.CJ-16-0464"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. <i>Clin Ther<\/i> 2016; 38: 2248\u20132264.","DOI":"10.1016\/j.clinthera.2016.08.008"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Verbrugge EH. Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure. <i>Curr Heart Fail Rep<\/i> 2017; 14: 275\u2013283.","DOI":"10.1007\/s11897-017-0340-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. R\u00e5dholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). <i>Circulation<\/i> 2018; 138: 458\u2013468.","DOI":"10.1161\/CIRCULATIONAHA.118.034222"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, et al. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. <i>J Am Soc Hypertens<\/i> 2017; 11: 604\u2013612.","DOI":"10.1016\/j.jash.2017.07.005"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/1\/10\/1_CR-19-0070\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T23:15:16Z","timestamp":1570835716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/1\/10\/1_CR-19-0070\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-19-0070","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]}}}